Sanofi Genzyme

Sanofi Genzyme (also known as Genzyme Corporation) is a biotech company that specializes in rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. It is engaged in the development of specialty care therapies to target a range of serious medical conditions. In addition, the company operates RegistryNXT, a web-based technology platform designed to collect patient clinical data related to the onset, progression, and treatment course of Gaucher, Fabry, MPS I, and Pompe diseases.
TypeSubsidiary
HQCambridge, MA, US
Founded1981
Websitesanofigenzyme.com
Cybersecurity ratingAMore
Sanofi Genzyme was founded in 1981 and is headquartered in Cambridge, MA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Sanofi Genzyme

Bill Sibold

Bill Sibold

Executive Vice President and Head of Sanofi Genzyme
Paul Hudson

Paul Hudson

Chief Executive Officer
Manuela Buxo

Manuela Buxo

Sr Vice President, Region Head Europe
Olivier Charmeil

Olivier Charmeil

Executive Vice President, General Medicines
Charles Castano

Charles Castano

Global Digital Head
Jean-Baptiste Chasseloup de Chatillon

Jean-Baptiste Chasseloup de Chatillon

Executive Vice President, Chief Financial Officer
Show more

Sanofi Genzyme Office Locations

Sanofi Genzyme has offices in Cambridge, Boston, Baltimore, Bridgewater Township and in 19 other locations
Cambridge, MA, US (HQ)
50 Binney St
Boston, MA, US
Allston
Copenhagen, DK
Østerbro
Show all (23)

Sanofi Genzyme Financials and Metrics

Summary Metrics

Founding Date

1981

Sanofi Genzyme Revenue

Sanofi Genzyme's revenue was reported to be €10.43 b in FY, 2019 which is a 26.1% increase from the previous period.
EURFY, 2017FY, 2018FY, 2019

Revenue

6.7b8.3b10.4b

Revenue growth, %

24%26%
Show all financial metrics

Sanofi Genzyme Operating Metrics

Sep, 2018Nov, 2020

Countries

100100

Partners

100

Patents (US)

605

Products

25
Show all operating metrics

Sanofi Genzyme Acquisitions / Subsidiaries

Company NameDateDeal Size
BioenvisionMay 29, 2007$345 m
AnorMEDOctober 17, 2006$580 m
BoneCare InternationalJuly 01, 2005$719 m
VerigenFebruary 09, 2005
ILEX Oncology, Inc.December 20, 2004$1 b
SangStatSeptember 10, 2003
BiomatrixDecember 18, 2000$738 m
PharmagenicsJune 16, 1997$28 m

Sanofi Genzyme Revenue Breakdown

Embed Graph

Sanofi Genzyme revenue breakdown by geographic segment: 20.8% from Europe, 56.9% from United States, 10.4% from Rest of the world and 11.8% from Emerging markets

Sanofi Genzyme Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Sanofi Genzyme Online and Social Media Presence

Embed Graph

Sanofi Genzyme News and Updates

Olipudase alfa demonstrated significant improvement in lung function and spleen volume in patients with ASMD

Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated significant improvement in lung function and spleen volume in patients with acid sphingomyelinase deficiency (ASMD). Results from two separate clinical trials of adult and pediatric patients were presented at th…

Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings

Additional positive results were announced from Part A of a pivotal Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). As previously reported, the trial met both of its co-primary and all key secondary endpoin…

Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease

Genetic testing and counseling through PD GENEration provides people with Parkinson's disease with detailed knowledge of their genetic status relative to key Parkinson's-related genes, ultimately empowering them to know more about their own disease. GBA, LRRK2 and SNCA are examples of genes associat…

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab), recommending to extend the approval in the European Union (EU) to include children aged 6 to 11 years with severe atopic dermatitis who are candidates for s…
Show more

Sanofi Genzyme Frequently Asked Questions

  • When was Sanofi Genzyme founded?

    Sanofi Genzyme was founded in 1981.

  • Who are Sanofi Genzyme key executives?

    Sanofi Genzyme's key executives are Bill Sibold, Paul Hudson and Manuela Buxo.

  • How many employees does Sanofi Genzyme have?

    Sanofi Genzyme has 10,077 employees.

  • What is Sanofi Genzyme revenue?

    Latest Sanofi Genzyme annual revenue is €10.4 b.

  • What is Sanofi Genzyme revenue per employee?

    Latest Sanofi Genzyme revenue per employee is €1 m.

  • Who are Sanofi Genzyme competitors?

    Competitors of Sanofi Genzyme include Biogen, Amgen and Amicus Therapeutics.

  • Where is Sanofi Genzyme headquarters?

    Sanofi Genzyme headquarters is located at 50 Binney St, Cambridge.

  • Where are Sanofi Genzyme offices?

    Sanofi Genzyme has offices in Cambridge, Boston, Baltimore, Bridgewater Township and in 19 other locations.

  • How many offices does Sanofi Genzyme have?

    Sanofi Genzyme has 23 offices.